PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 29, 2026Journal of Clinical Apheresis0 citations

Double Filtration Plasmapheresis for Refractory Hypercholesterolemia in Drug‐Induced Cholestasis: A Case Report

View Full Paper
YLYuling LiangWZWenjian ZhuDYDi Yang

Key Points

  • To explore the effectiveness of double filtration plasmapheresis in treating severe hypercholesterolemia caused by drug-induced cholestasis.
  • Case report of a 56-year-old male with severe cholestatic hepatitis from herbal agents.
  • Conducted laboratory investigations to assess cholesterol and bilirubin levels.
  • Applied two sessions of double filtration plasmapheresis.
  • Achieved over 90% reduction in total cholesterol levels.
  • Simultaneous improvement in bilirubin and liver enzyme levels.
  • Sustained normal cholesterol and bilirubin levels at one-year follow-up.

Abstract

ABSTRACT While lipoprotein apheresis (LA) is established for lipid management in primary biliary cholangitis, the role of apheresis techniques in drug‐induced cholestatic liver disease remains unexplored. We report the novel application of double filtration plasmapheresis (DFPP) for rapid reversal of severe hypercholesterolemia in iatrogenic cholestasis, where conventional therapies failed or were contraindicated. A 56‐year‐old male developed severe cholestatic hepatitis following the use of herbal agents. Laboratory investigation revealed extreme hypercholesterolemia, with a total cholesterol (TC) of 41.39 mmol/L and a low‐density lipoprotein cholesterol (LDL‐c) of 38 mmol/L. Standard medical therapy proved ineffective. Two sessions of DFPP resulted in > 90% reduction in cholesterol levels and simultaneous improvement in bilirubin and liver enzymes, with sustained normal levels at 1‐year follow‐up. DFPP may serve as a novel rescue therapy for drug‐induced cholestatic hypercholesterolemia, providing simultaneous removal of cholesterol and bilirubin where other treatments are ineffective or at high risk.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liang et al. (2026) studied this question.

synapsesocial.com/papers/69c8c324de0f0f753b39db05https://doi.org/10.1002/jca.70117
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic plasmapheresis and cascade filtration – Advances in technology and clinical applications2006 · 3 citations
  2. 2Management of lipoprotein-x accumulation in severe cholestasis by semi-selective ldl-apheresis1991 · 17 citations
  3. 3Verrucous plane xanthomas secondary to lipoprotein X dyslipidemia in the context of cholestatic fulminant hepatitis: A case report2021 · 4 citations
  4. 4Double Filtration Plasmapheresis (DFPP) in Severe Hypertriglyceridemia Patients - a Pilot Study2022 · 3 citations
  5. 5Improvement of refractory pruritus after lipoprotein‐apheresis in arthrogryposis‐renal failure‐cholestasis syndrome2017 · 5 citations